MX242553B - Derivados aromaticos que contienen nitrogeno. - Google Patents

Derivados aromaticos que contienen nitrogeno.

Info

Publication number
MX242553B
MX242553B MXPA03003362A MX242553B MX 242553 B MX242553 B MX 242553B MX PA03003362 A MXPA03003362 A MX PA03003362A MX 242553 B MX242553 B MX 242553B
Authority
MX
Mexico
Prior art keywords
aromatic ring
ring compounds
nitrogenous aromatic
general formula
following general
Prior art date
Application number
Other languages
English (en)
Inventor
Tatsuo Watanabe
Original Assignee
Eisai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai Co Ltd filed Critical Eisai Co Ltd
Publication of MXPA03003362A publication Critical patent/MXPA03003362A/es
Publication of MX242553B publication Critical patent/MX242553B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/26—Radicals substituted by halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/68—One oxygen atom attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/233—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/48—Acylated amino or imino radicals by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof, e.g. carbonylguanidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/06—1,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MXPA03003362 2000-10-20 2001-10-19 Derivados aromaticos que contienen nitrogeno. MX242553B (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2000320420 2000-10-20
JP2000386195 2000-12-20
JP2001046685 2001-02-22
PCT/JP2001/009221 WO2002032872A1 (en) 2000-10-20 2001-10-19 Nitrogenous aromatic ring compounds

Publications (2)

Publication Number Publication Date
MXPA03003362A MXPA03003362A (es) 2003-08-01
MX242553B true MX242553B (es) 2006-12-06

Family

ID=27344984

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03003362 MX242553B (es) 2000-10-20 2001-10-19 Derivados aromaticos que contienen nitrogeno.

Country Status (25)

Country Link
US (5) US7253286B2 (es)
EP (3) EP1506962B1 (es)
JP (3) JP3712393B2 (es)
KR (2) KR100589032B1 (es)
CN (3) CN101024627A (es)
AT (3) ATE399766T1 (es)
AU (4) AU2001295986B2 (es)
BE (1) BE2015C055I2 (es)
CA (1) CA2426461C (es)
CY (2) CY1107491T1 (es)
DE (3) DE60134679D1 (es)
DK (1) DK1415987T3 (es)
ES (2) ES2282299T3 (es)
FR (1) FR15C0070I2 (es)
HU (2) HU230302B1 (es)
IL (3) IL155447A0 (es)
LU (1) LU92858I2 (es)
MX (1) MX242553B (es)
NL (1) NL300764I2 (es)
NO (3) NO326781B1 (es)
NZ (1) NZ525324A (es)
PT (1) PT1415987E (es)
RU (1) RU2264389C3 (es)
TW (1) TWI304061B (es)
WO (1) WO2002032872A1 (es)

Families Citing this family (277)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7517880B2 (en) * 1997-12-22 2009-04-14 Bayer Pharmaceuticals Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
EP1158985B1 (en) 1999-01-13 2011-12-28 Bayer HealthCare LLC OMEGA-CARBOXY ARYL SUBSTITUTED DIPHENYL UREAS AS p38 KINASE INHIBITORS
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
DE60134679D1 (de) * 2000-10-20 2008-08-14 Eisai R&D Man Co Ltd Stickstoff enthaltende aromatische Heterozyklen
US6821987B2 (en) * 2001-04-27 2004-11-23 Kirin Beer Kabushiki Kaisha Quinoline derivatives and quinazoline derivatives having azolyl group
US7294633B2 (en) * 2001-05-14 2007-11-13 Novartis Ag Oxazolo-and furopyrimidines and their use in medicaments against tumors
DE60233736D1 (de) 2001-06-22 2009-10-29 Kirin Pharma K K Chinolinderivat und chinazolinderivat, die die selbstphosphorylierung des hepatocytus-proliferator-rezeptors hemmen, und diese enthaltende medizinische zusammensetzung
GB0119249D0 (en) 2001-08-07 2001-10-03 Novartis Ag Organic compounds
US7323469B2 (en) 2001-08-07 2008-01-29 Novartis Ag 7H-pyrrolo[2,3-d]pyrimidine derivatives
WO2003033472A1 (fr) * 2001-10-17 2003-04-24 Kirin Beer Kabushiki Kaisha Derives de quinoline ou de quinazoline inhibant l'autophosphorylation de recepteurs du facteur de croissance des fibroblastes
WO2003068229A1 (en) 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
EP1478358B1 (en) 2002-02-11 2013-07-03 Bayer HealthCare LLC Sorafenib tosylate for the treatment of diseases characterized by abnormal angiogenesis
EP1481678A4 (en) * 2002-03-05 2009-12-30 Eisai R&D Man Co Ltd ANTITUMORAL AGENT CONTAINING A SULFONAMIDE-CONTAINING HETEROCYCLIC COMPOUND AND AN ANGIOGENESIS INHIBITOR
WO2003093238A1 (fr) * 2002-05-01 2003-11-13 Kirin Beer Kabushiki Kaisha Derives de quinoleine et derives de quinazoline inhibiteurs de l'autophosphorylation du recepteur du facteur stimulant la proliferation des macrophages
AR037647A1 (es) 2002-05-29 2004-12-01 Novartis Ag Derivados de diarilurea utiles para el tratamiento de enfermedades dependientes de la cinasa de proteina
CA2493667C (en) 2002-08-08 2010-04-27 Amgen Inc. Vanilloid receptor ligands and their use in treatments
CN100339376C (zh) * 2002-08-30 2007-09-26 卫材R&D管理有限公司 含氮芳环衍生物
DK1559715T3 (da) * 2002-10-21 2007-12-27 Kirin Brewery N-{2-chlor-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-N'-(5-methyl-3-isoxazolyl) - ureasalt i krystallinsk form
WO2004039782A1 (ja) * 2002-10-29 2004-05-13 Kirin Beer Kabushiki Kaisha Ｆｌｔ３自己リン酸化を阻害するキノリン誘導体およびキナゾリン誘導体並びにそれらを含有する医薬組成物
TW200418466A (en) * 2002-11-06 2004-10-01 Smithkline Beecham Corp Chemical compounds
UY28213A1 (es) 2003-02-28 2004-09-30 Bayer Pharmaceuticals Corp Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
EP1604665B1 (en) 2003-03-10 2011-05-11 Eisai R&D Management Co., Ltd. C-kit kinase inhibitor
MXPA05010782A (es) * 2003-04-07 2005-12-12 Axys Pharm Inc Nuevos hidroxamatos como agentees terapeuticos.
DK1613604T3 (da) * 2003-04-16 2006-10-30 Huntsman Adv Mat Switzerland 1-imidazolylmethyl-substituerede 2-naphtholer og deres anvendelse som acceleratorer til lavtemperaturhærdning
US20070117842A1 (en) * 2003-04-22 2007-05-24 Itaru Arimoto Polymorph of 4-[3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy]-7-methoxy-6- quinolinecarboxamide and a process for the preparation of the same
WO2004093812A2 (en) * 2003-04-22 2004-11-04 Irm Llc Compounds that induce neuronal differentiation in embryonic stem cells
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
CA2526636C (en) 2003-05-20 2012-10-02 Bayer Pharmaceuticals Corporation Diaryl ureas for diseases mediated by pdgfr
US8309562B2 (en) 2003-07-03 2012-11-13 Myrexis, Inc. Compounds and therapeutical use thereof
CL2004001834A1 (es) 2003-07-23 2005-06-03 Bayer Pharmaceuticals Corp Compuesto 4-{4-[3-(4-cloro-3-trifluorometilfenil)-ureido]-3-fluorofenoxi}-piridin-2-metilamida, inhibidor de la raf, vegfr, p38 y pdgfr quinasas, sus sales; composiicon farmaceutica; combinacion farmaceutica; y su uso para tratar trastornos hiperprol
WO2005019174A1 (en) * 2003-08-20 2005-03-03 Axys Pharmaceuticals, Inc. Acetylene derivatives as inhibitors of histone deacetylase
EP2609919A3 (en) * 2003-09-26 2014-02-26 Exelixis, Inc. c-Met modulators and methods of use
MXPA06003615A (es) * 2003-09-30 2006-06-05 Amgen Inc Ligandos del receptor vanilloide y su uso en tratamientos.
EP1683785B1 (en) * 2003-11-11 2013-10-16 Eisai R&D Management Co., Ltd. Urea derivative and process for producing the same
AU2004291147A1 (en) * 2003-11-13 2005-06-02 Ambit Biosciences Corporation Urea derivatives as kinase modulators
PE20051046A1 (es) * 2003-11-28 2006-01-11 Novartis Ag Derivados de diaril-urea en el tratamiento de enfermedades dependientes de la quinasa de proteina
DE10357510A1 (de) * 2003-12-09 2005-07-07 Bayer Healthcare Ag Heteroarylsubstituierte Benzole
JP4503022B2 (ja) * 2003-12-23 2010-07-14 ファイザー・インク 新規キノリン誘導体
AU2004309217B2 (en) * 2003-12-25 2008-11-06 Eisai R&D Management Co., Ltd Crystal of salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)amino-phenoxy)-7-methoxy-6-quinolinecarboxamide or of solvate thereof and processes for producing these
WO2005073224A2 (en) 2004-01-23 2005-08-11 Amgen Inc Quinoline quinazoline pyridine and pyrimidine counds and their use in the treatment of inflammation angiogenesis and cancer
KR20070026390A (ko) 2004-01-23 2007-03-08 암젠 인코포레이션 화합물 및 사용방법
CA2556239A1 (en) 2004-02-11 2005-08-25 Amgen Inc. Vanilloid receptor ligands and their use in treatments
MY139645A (en) 2004-02-11 2009-10-30 Amgen Inc Vanilloid receptor ligands and their use in treatments
TW200530236A (en) 2004-02-23 2005-09-16 Chugai Pharmaceutical Co Ltd Heteroaryl phenylurea
JPWO2005082855A1 (ja) 2004-02-27 2007-10-25 エーザイ・アール・アンド・ディー・マネジメント株式会社 新規ピリジン誘導体およびピリミジン誘導体（２）
DE102004017438A1 (de) * 2004-04-08 2005-11-03 Bayer Healthcare Ag Hetaryloxy-substituierte Phenylaminopyrimidine
US7459562B2 (en) 2004-04-23 2008-12-02 Bristol-Myers Squibb Company Monocyclic heterocycles as kinase inhibitors
TW200538453A (en) 2004-04-26 2005-12-01 Bristol Myers Squibb Co Bicyclic heterocycles as kinase inhibitors
MXPA06012394A (es) 2004-04-30 2007-01-31 Bayer Pharmaceuticals Corp Derivados de pirazolilurea sustituidos utiles en el tratamiento de cancer.
AU2005239878B9 (en) * 2004-05-06 2010-01-07 Warner-Lambert Company Llc 4-phenylamino-quinazolin-6-yl-amides
AU2005245386B2 (en) 2004-05-07 2008-11-27 Amgen Inc. Nitrogenated heterocyclic derivatives as protein kinase modulators and use for the treatment of angiogenesis and cancer
WO2005121125A1 (en) * 2004-06-09 2005-12-22 Pfizer Inc. Ether-linked heteroaryl compounds
US7439246B2 (en) 2004-06-28 2008-10-21 Bristol-Myers Squibb Company Fused heterocyclic kinase inhibitors
US7432373B2 (en) 2004-06-28 2008-10-07 Bristol-Meyers Squibb Company Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
US7173031B2 (en) * 2004-06-28 2007-02-06 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
WO2006014325A2 (en) * 2004-07-02 2006-02-09 Exelixis, Inc. C-met modulators and method of use
US7507748B2 (en) * 2004-07-22 2009-03-24 Amgen Inc. Substituted aryl-amine derivatives and methods of use
MX2007001216A (es) * 2004-07-30 2007-03-23 Methylgene Inc Inhibidores de la senalizacion del receptor del factor de crecimiento endotelial vascular y del receptor del factor de crecimiento del hepatocito.
WO2006030941A1 (ja) 2004-09-13 2006-03-23 Eisai R & D Management Co., Ltd. スルホンアミド含有化合物の血管新生阻害物質との併用
US8772269B2 (en) 2004-09-13 2014-07-08 Eisai R&D Management Co., Ltd. Use of sulfonamide-including compounds in combination with angiogenesis inhibitors
PE20060664A1 (es) 2004-09-15 2006-08-04 Novartis Ag Amidas biciclicas como inhibidores de cinasa
ES2322175T3 (es) 2004-09-17 2009-06-17 EISAI R&D MANAGEMENT CO., LTD. Composicion medicinal con estabilidad mejorada y gelificacion reducida.
GB0421525D0 (en) * 2004-09-28 2004-10-27 Novartis Ag Inhibitors of protein kineses
US20070054916A1 (en) * 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
BRPI0517232A (pt) 2004-11-02 2008-10-07 Banyu Pharma Co Ltd composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, ativador da glicocinase, e, agentes terapêuticos e/ou profiláticos para diabetes e para obesidade
US7652009B2 (en) 2004-11-30 2010-01-26 Amgem Inc. Substituted heterocycles and methods of use
CA2592900A1 (en) 2005-01-03 2006-07-13 Myriad Genetics Inc. Nitrogen containing bicyclic compounds and therapeutical use thereof
US8258145B2 (en) 2005-01-03 2012-09-04 Myrexis, Inc. Method of treating brain cancer
WO2006096270A1 (en) * 2005-02-03 2006-09-14 Vertex Pharmaceuticals Incorporated Pyrrolopyrimidines useful as inhibitors of protein kinase
WO2006089311A1 (en) 2005-02-15 2006-08-24 Amgen Inc. Vanilloid receptor ligands and their use in treatments
JO2787B1 (en) 2005-04-27 2014-03-15 امجين إنك, Alternative amide derivatives and methods of use
KR101378716B1 (ko) * 2005-05-20 2014-04-10 메틸진 인코포레이티드 Ｖｅｇｆ 수용체 및 ｈｇｆ 수용체 신호전달의 억제제
CN101228161B (zh) 2005-05-20 2012-10-10 沃泰克斯药物股份有限公司 适用作蛋白激酶抑制剂的吡咯并吡啶类
CN101233111A (zh) * 2005-06-23 2008-07-30 卫材R&D管理有限公司 4-（3-氯-4-（环丙基氨基羰基）氨基苯氧基）-7-甲氧基-6-喹啉羧酸酰胺的无定形盐及其制备方法
US7550483B2 (en) 2005-06-23 2009-06-23 Eisai R&D Management Co., Ltd. Amorphous salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide and process for preparing the same
MX2007015679A (es) 2005-06-30 2008-02-21 Amgen Inc Inhibidores de quinasa bis-aril y su uso en el tratamiento de inflamacion, angiogenesis y cancer.
TW200740820A (en) * 2005-07-05 2007-11-01 Takeda Pharmaceuticals Co Fused heterocyclic derivatives and use thereof
JP5281287B2 (ja) 2005-07-13 2013-09-04 Ｍｓｄ株式会社 ヘテロ環置換ベンズイミダゾール誘導体
WO2007015569A1 (ja) 2005-08-01 2007-02-08 Eisai R & D Management Co., Ltd. 血管新生阻害物質の効果を予測する方法
JP4989476B2 (ja) * 2005-08-02 2012-08-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質の効果を検定する方法
WO2007018137A1 (ja) 2005-08-05 2007-02-15 Chugai Seiyaku Kabushiki Kaisha マルチキナーゼ阻害剤
CN101277689B (zh) * 2005-08-08 2011-01-12 詹森药业有限公司 噻唑并嘧啶类激酶抑制剂
PT1889836E (pt) * 2005-08-24 2013-08-28 Eisai R&D Man Co Ltd Novo derivado de piridina e derivado de pirimidina (3)
WO2007026864A1 (ja) * 2005-09-01 2007-03-08 Eisai R & D Management Co., Ltd. 崩壊性の改善された医薬組成物の製造方法
GT200600411A (es) * 2005-09-13 2007-05-21 Novartis Ag Combinaciones que comprenden un inhibidor del receptor del factor de crecimiento endotelial vascular
CA2623958C (en) 2005-09-30 2013-05-28 Banyu Pharmaceutical Co., Ltd. 2-heteroaryl-substituted indole derivative
EP1940844B1 (en) * 2005-10-28 2009-09-30 Irm Llc Compounds and compositions as protein kinase inhibitors
US20090053236A1 (en) * 2005-11-07 2009-02-26 Eisai R & D Management Co., Ltd. USE OF COMBINATION OF ANTI-ANGIOGENIC SUBSTANCE AND c-kit KINASE INHIBITOR
EP1964837A4 (en) * 2005-11-22 2010-12-22 Eisai R&D Man Co Ltd Antitumor agent against multiple myeloma
TW201018662A (en) 2005-12-12 2010-05-16 Astrazeneca Ab Alkylsulphonamide quinolines
US8580798B2 (en) 2005-12-21 2013-11-12 Bayer Intellectual Property Gmbh Substituted pyrimidine derivatives useful in the treatment of cancer and other disorders
SMP200800041B (it) * 2005-12-21 2009-07-14 Novartis Ag Derivati di pirimidinil-aril-urea attivi come-fgf-inibitori
TW200804349A (en) * 2005-12-23 2008-01-16 Kalypsys Inc Novel substituted pyrimidinyloxy ureas as inhibitors of protein kinases
US7868177B2 (en) 2006-02-24 2011-01-11 Amgen Inc. Multi-cyclic compounds and method of use
AU2007221049A1 (en) * 2006-02-28 2007-09-07 Amgen Inc. Cinnoline and quinazoline derivates as phosphodiesterase 10 inhibitors
UY30183A1 (es) * 2006-03-02 2007-10-31 Astrazeneca Ab Derivados de quinolina
GB0604937D0 (en) * 2006-03-10 2006-04-19 Novartis Ag Organic compounds
GB0605120D0 (en) 2006-03-14 2006-04-26 Novartis Ag Organic Compounds
PE20080145A1 (es) 2006-03-21 2008-02-11 Janssen Pharmaceutica Nv Tetrahidro-pirimidoazepinas como moduladores de trpv1
US7692024B2 (en) * 2006-05-05 2010-04-06 Tk Holdings, Inc. Gas generant compositions
US8088235B2 (en) * 2006-05-05 2012-01-03 Tk Holdings, Inc. Gas generant compositions
WO2007136103A1 (ja) * 2006-05-18 2007-11-29 Eisai R & D Management Co., Ltd. 甲状腺癌に対する抗腫瘍剤
WO2008035209A2 (en) * 2006-05-30 2008-03-27 Methylgene Inc. Inhibitors of protein tyrosine kinase activity
JPWO2008001956A1 (ja) 2006-06-29 2009-12-03 エーザイ・アール・アンド・ディー・マネジメント株式会社 肝線維症治療剤
US20080004253A1 (en) * 2006-06-30 2008-01-03 Bryan James Branstetter Thiazolopyrimidine modulators of TRPV1
AR062207A1 (es) 2006-08-04 2008-10-22 Takeda Pharmaceutical Derivados de imidazopiridazina inhibidores de quinasas utiles para prevenir y/o tratar el cancer.
EP2062886B1 (en) 2006-08-23 2011-11-30 Eisai R&D Management Co., Ltd. Salt of phenoxypyridine derivative or crystal thereof and process for producing the same
WO2008026748A1 (fr) 2006-08-28 2008-03-06 Eisai R & D Management Co., Ltd. Agent antitumoral pour cancer gastrique non différencié
KR101432318B1 (ko) 2006-08-31 2014-08-20 에자이 알앤드디 매니지먼트 가부시키가이샤 페녹시피리딘 유도체의 제조 방법
US7790885B2 (en) * 2006-08-31 2010-09-07 Eisai R&D Management Co., Ltd. Process for preparing phenoxypyridine derivatives
DE112007002257T5 (de) * 2006-09-30 2009-07-30 TK Holdings, Inc., Armada Gaserzeugungsmittelzusammensetzungen
US8470859B2 (en) 2006-10-23 2013-06-25 Takeda Pharmaceutical Company Limited Iminopyridine derivative and use thereof
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
MX2009006543A (es) 2006-12-20 2009-06-26 Amgen Inc Compuestos heterociclicos y su uso en el tratamiento de la inflamacion, angiogenesis y cancer.
BRPI0720741A2 (pt) 2006-12-22 2014-01-28 Hoffmann La Roche Derivados de primidila como inibidores da proteína cinase.
JP2010514777A (ja) * 2006-12-26 2010-05-06 ファーマサイクリックス，インク． 併用療法においてヒストンデアセチラーゼ阻害剤を使用し、バイオマーカーをモニタする方法
CA2675736A1 (en) 2007-01-19 2008-07-24 Eisai R&D Management Co., Ltd. Composition for treatment of pancreatic cancer
KR101445892B1 (ko) * 2007-01-29 2014-09-29 에자이 알앤드디 매니지먼트 가부시키가이샤 미분화형 위암 치료용 조성물
KR101483805B1 (ko) * 2007-01-30 2015-01-16 파마시클릭스, 인코포레이티드 히스톤 데아세틸라제 억제제에 대한 암 내성을 확인하는 방법
BRPI0807014A2 (pt) * 2007-02-09 2014-04-22 Takeda Pharmaceutical Composto, pró-droga, agente farmacêutico, métodos para melhorar a resistência a insulina em um mamífero, método para a profilaxia ou o tratamento de diabetes em um mamífero, e, uso de um composto.
US8148532B2 (en) 2007-03-14 2012-04-03 Guoqing Paul Chen Spiro substituted compounds as angiogenesis inhibitors
US20110189167A1 (en) * 2007-04-20 2011-08-04 Flynn Daniel L Methods and Compositions for the Treatment of Myeloproliferative Diseases and other Proliferative Diseases
WO2008131253A1 (en) * 2007-04-20 2008-10-30 Deciphera Pharmaceuticals, Llc Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
US20110160305A1 (en) * 2007-05-01 2011-06-30 Marty Jones Oral Delivery of Therapeutic Doses of Glutathione
WO2008150015A1 (en) 2007-06-05 2008-12-11 Takeda Pharmaceutical Company Limited Heterobicyclic compounds as kinase inhibitors
JP5270553B2 (ja) * 2007-08-23 2013-08-21 武田薬品工業株式会社 複素環化合物およびその用途
JP5656634B2 (ja) 2007-08-29 2015-01-21 メチルジーン インコーポレイテッド タンパク質チロシンキナーゼ活性の阻害剤
WO2009035949A2 (en) * 2007-09-13 2009-03-19 Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors
EA018414B1 (ru) 2007-10-11 2013-07-30 ГЛЭКСОСМИТКЛАЙН ЭлЭлСи ИНГИБИТОРЫ sEH И ИХ ПРИМЕНЕНИЕ
CA2703257C (en) * 2007-10-29 2013-02-19 Amgen Inc. Benzomorpholine derivatives and methods of use
TWI440638B (zh) * 2007-10-30 2014-06-11 Otsuka Pharma Co Ltd 雜環化合物及其藥學組成物
US8952035B2 (en) 2007-11-09 2015-02-10 Eisai R&D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
CN101969951B (zh) * 2007-11-16 2012-10-31 雅培制药有限公司 化合物在制备治疗关节炎的药物中的方法
BRPI0820171B8 (pt) 2007-11-16 2021-05-25 Rigel Pharmaceuticals Inc compostos de carboxamida, sulfonamida e amina para distúrbios metabólicos, composição farmacêutica, e, uso dos mesmos
JP2009132660A (ja) 2007-11-30 2009-06-18 Eisai R & D Management Co Ltd 食道癌治療用組成物
WO2009076631A1 (en) 2007-12-12 2009-06-18 Rigel Pharmaceuticals, Inc. Carboxamide, sulfonamide and amine compounds for metabolic disorders
EP2224929B1 (en) 2007-12-17 2016-05-04 Janssen Pharmaceutica, N.V. Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of trpv1
CA2710122A1 (en) 2007-12-20 2009-07-02 Novartis Ag Thiazole derivatives used as pi 3 kinase inhibitors
JP5693239B2 (ja) 2008-01-23 2015-04-01 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ４−ピリジノン化合物および癌についてのその使用
MX2010008187A (es) 2008-01-29 2010-08-10 Eisai R&D Man Co Ltd Uso combinado de inhibidor de angiogenesis y taxano.
US20090227556A1 (en) * 2008-01-31 2009-09-10 Eisai R&D Management Co., Ltd. Receptor tyrosine kinase inhibitors comprising pyridine and pyrimidine derivatives
US20100311972A1 (en) * 2008-02-18 2010-12-09 Mitsuo Nagai Method for producing phenoxypyridine derivative
WO2009109035A1 (en) * 2008-03-05 2009-09-11 Methylgene Inc. Inhibitors of protein tyrosine kinase activity
SI2268623T1 (sl) * 2008-03-17 2016-01-29 Ambit Biosciences Corporation Derivati kinazolina kot modulatorji raf-kinaze in postopki uporabe le-teh
TWI438193B (zh) * 2008-04-10 2014-05-21 Taiho Pharmaceutical Co Ltd 醯基硫脲化合物或其鹽、及其用途
AU2009239500B2 (en) * 2008-04-21 2014-01-30 Lexicon Pharmaceuticals, Inc. LIMK2 inhibitors, compositions comprising them, and methods of their use
US20110039892A1 (en) * 2008-04-23 2011-02-17 Takeda Pharmaceutical Company Limited Iminopyridine derivative and use thereof
NZ588909A (en) * 2008-04-23 2012-08-31 Takeda Pharmaceutical Iminopyridine derivatives and use thereof
EP2276761B1 (en) 2008-04-23 2015-07-29 Rigel Pharmaceuticals, Inc. Carboxamide compounds for the treatment of metabolic disorders
US8481569B2 (en) 2008-04-23 2013-07-09 Takeda Pharmaceutical Company Limited Iminopyridine derivatives and use thereof
CN102014627B (zh) * 2008-04-30 2014-10-29 国家卫生研究院 作为极光激酶抑制剂的稠合双环嘧啶化合物
SG192543A1 (en) 2008-05-05 2013-08-30 Merck Canada Inc 3, 4 - substituted piperidine derivatives as renin inhibitors
WO2009151910A2 (en) * 2008-05-25 2009-12-17 Wyeth Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
AU2009267161B2 (en) * 2008-07-03 2014-11-06 Merck Patent Gmbh Naphthyridininones as Aurora kinase inhibitors
US8211911B2 (en) 2008-08-19 2012-07-03 Guoqing Paul Chen Compounds as kinase inhibitors
RS53382B (en) 2008-08-20 2014-10-31 Zoetis Llc PIROL [2,3-D] PIRIMIDINE COMPOUNDS
UA104147C2 (uk) 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
EP2331530B8 (en) 2008-09-26 2013-12-25 National Health Research Institutes Fused multicyclic compounds as protein kinase inhibitors
WO2010045095A1 (en) 2008-10-14 2010-04-22 Ning Xi Compounds and methods of use
JP5579619B2 (ja) 2008-12-01 2014-08-27 武田薬品工業株式会社 複素環化合物およびその用途
JO3101B1 (ar) 2008-12-02 2017-09-20 Takeda Pharmaceuticals Co مشتقات بنزوثيازول كعوامل مضادة للسرطان
JO3265B1 (ar) * 2008-12-09 2018-09-16 Novartis Ag مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض
TW202241853A (zh) 2009-01-16 2022-11-01 美商艾克塞里克斯公司 包含n-(4-{[6,7-雙(甲氧基)喹啉-4-基]氧基}苯基)-n'-(4-氟苯基)環丙烷-1,1-二甲醯胺之蘋果酸鹽之醫藥組合物及其用途
KR20110133048A (ko) * 2009-03-21 2011-12-09 닝 시 아미노 에스테르 유도체, 그의 염 및 이용 방법
WO2010108503A1 (en) 2009-03-24 2010-09-30 Life & Brain Gmbh Promotion of neuronal integration in neural stem cell grafts
US8603521B2 (en) 2009-04-17 2013-12-10 Pharmacyclics, Inc. Formulations of histone deacetylase inhibitor and uses thereof
CN101671301B (zh) * 2009-05-05 2014-02-26 江苏省药物研究所有限公司 杂环取代的二苯脲类衍生物及其用途
US8293753B2 (en) 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
US20110112121A1 (en) * 2009-07-06 2011-05-12 Joerg Berghausen Pharmaceutical Compositions and Solid Forms
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
CN102470133B (zh) * 2009-08-19 2013-08-28 卫材R&D管理有限公司 含有喹啉衍生物的药物组合物
NZ598455A (en) * 2009-09-03 2014-03-28 Allergan Inc Compounds as tyrosine kinase modulators
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
SG184987A1 (en) 2010-04-22 2012-11-29 Vertex Pharma Process of producing cycloalkylcarboxamido-indole compounds
BR112012032462A2 (pt) 2010-06-25 2016-11-08 Eisai R&D Man Co Ltd agente antitumoral empregando compostos que, em combinação, têm efeito inibidor de quinase.
JP5789259B2 (ja) 2010-07-16 2015-10-07 協和発酵キリン株式会社 含窒素芳香族複素環誘導体
KR101032732B1 (ko) * 2010-07-29 2011-05-06 김선자 방범 창호프레임
EP2423208A1 (en) * 2010-08-28 2012-02-29 Lead Discovery Center GmbH Pharmaceutically active compounds as Axl inhibitors
US11179500B2 (en) * 2011-02-24 2021-11-23 Emory University JAB1 inhibitory compositions for ossification and methods related thereto
US8962650B2 (en) 2011-04-18 2015-02-24 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
EP3444363B1 (en) 2011-06-03 2020-11-25 Eisai R&D Management Co., Ltd. Biomarkers for prediciting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
SG10201604682VA (en) 2011-06-10 2016-07-28 Merck Patent Gmbh Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity
MX365393B (es) 2011-09-13 2019-05-31 Pharmacyclics Llc Formulaciones de inhibidor de histona deacetilasa en combinación con bendamustina y usos de las mismas.
US8841301B2 (en) 2011-09-26 2014-09-23 Bristol-Myers Squibb Company Selective NR2B antagonists
TWI594986B (zh) * 2011-12-28 2017-08-11 Taiho Pharmaceutical Co Ltd Antineoplastic agent effect enhancer
CN103508961B (zh) * 2012-06-26 2015-07-22 中美冠科生物技术（太仓）有限公司 抗肿瘤药物
US20150225369A1 (en) * 2012-08-29 2015-08-13 Merck Patent Gmbh Ddr2 inhibitors for the treatment of osteoarthritis
MX2015004979A (es) * 2012-12-21 2015-07-17 Eisai R&D Man Co Ltd Forma amorfa de derivado de quinolina y metodo para su produccion.
AR094812A1 (es) 2013-02-20 2015-08-26 Eisai R&D Man Co Ltd Derivado de piridina monocíclico como inhibidor del fgfr
US9475773B2 (en) 2013-04-19 2016-10-25 Astrazeneca Ab NK3 receptor antagonist compound (NK3RA) for use in a method for the treatment of polycystic ovary syndrome (PCOS)
ES2687968T3 (es) * 2013-05-14 2018-10-30 Eisai R&D Management Co., Ltd. Biomarcadores para pronosticar y evaluar la reactividad de sujetos con cáncer de endometrio a compuestos con lenvatinib
CA2915005C (en) 2013-06-26 2021-12-28 Eisai R&D Management Co., Ltd. Use of eribulin and lenvatinib as combination therapy for treatment of cancer
JP6800750B2 (ja) 2013-08-02 2020-12-16 ファーマサイクリックス エルエルシー 固形腫瘍の処置方法
CN103509005B (zh) * 2013-09-26 2015-04-08 苏州海特比奥生物技术有限公司 喹唑啉类化合物及其制备方法与应用
GEP20186887B (en) * 2014-04-04 2018-08-27 Pfizer Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
US10206877B2 (en) 2014-04-15 2019-02-19 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for the treatment of cystic fibrosis transmembrane conductance regulator mediated diseases
CN106660997B (zh) 2014-08-18 2019-05-21 卫材R&D管理有限公司 单环吡啶衍生物的盐及其晶体
BR112017002827B1 (pt) * 2014-08-28 2023-04-18 Eisai R&D Management Co., Ltd Derivado de quinolina altamente puro e método para produção do mesmo
MA40774A (fr) 2014-10-01 2017-08-08 Respivert Ltd Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38
CN105985289B (zh) * 2015-02-15 2018-12-21 正大天晴药业集团股份有限公司 一种乐伐替尼的制备方法
MX2017010474A (es) 2015-02-25 2017-11-28 Eisai R&D Man Co Ltd Metodo para suprimir el amargor de un derivado de quinoleina.
KR20240064733A (ko) 2015-03-04 2024-05-13 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
CN106046007B (zh) * 2015-04-07 2019-02-05 广东众生睿创生物科技有限公司 酪氨酸激酶抑制剂及包含该酪氨酸激酶抑制剂的药物组合物
SG11201710198YA (en) 2015-06-16 2018-01-30 Eisai R&D Man Co Ltd Anticancer agent
RU2718048C2 (ru) 2015-08-20 2020-03-30 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Противоопухолевое терапевтическое средство
CN107949559B (zh) * 2015-08-27 2020-12-11 辉瑞公司 作为irak4调节剂的双环稠合杂芳基或芳基化合物
CN107266363A (zh) * 2016-04-06 2017-10-20 杭州华东医药集团新药研究院有限公司 甲磺酸乐伐替尼药物杂质的制备方法
CZ2016240A3 (cs) 2016-04-27 2017-11-08 Zentiva, K.S. Soli lenvatinibu
WO2017211303A1 (en) 2016-06-07 2017-12-14 Jacobio Pharmaceuticals Co., Ltd. Novel heterocyclic derivatives useful as shp2 inhibitors
CN106243124B (zh) * 2016-07-29 2018-03-09 湖北民族学院 一种噻吩并嘧啶脲类化合物及其制备方法和应用
US9957233B1 (en) 2016-08-05 2018-05-01 Calitor Sciences, Llc Process for preparing substituted quinolin-4-ol compounds
WO2018028591A1 (zh) 2016-08-09 2018-02-15 殷建明 一种喹啉衍生物及其用途
TWI603962B (zh) 2016-09-10 2017-11-01 國立清華大學 含硫噁嗪化合物及其合成方法
WO2018059534A1 (zh) * 2016-09-30 2018-04-05 广东众生药业股份有限公司 酪氨酸激酶抑制剂的晶型、盐型以及制备方法
CN106854180B (zh) * 2016-11-30 2018-08-31 济南轩德化工有限公司 一种4-氯-7-甲氧基喹啉-6-酰胺的制备方法
CN110191705A (zh) 2016-12-01 2019-08-30 亚尼塔公司 治疗癌症的方法
CN110248660A (zh) * 2016-12-29 2019-09-17 雷迪博士实验室有限公司 甲磺酸乐伐替尼的固态形式
CN108299294A (zh) * 2017-01-11 2018-07-20 江苏恒瑞医药股份有限公司 一种乐伐替尼杂质的制备方法
CN106810512B (zh) * 2017-01-18 2019-09-10 江苏省中医药研究院 Idh2突变体抑制剂及其用途
WO2018145621A1 (zh) * 2017-02-07 2018-08-16 恩瑞生物医药科技（上海）有限公司 喹啉类化合物、其制备方法及其医药用途
ES2971448T3 (es) 2017-02-08 2024-06-05 Eisai R&D Man Co Ltd Composición farmacéutica para el tratamiento de tumores
TWI702951B (zh) 2017-02-15 2020-09-01 日商大鵬藥品工業股份有限公司 醫藥組成物
WO2018157411A1 (zh) * 2017-02-28 2018-09-07 深圳市塔吉瑞生物医药有限公司 取代的含氮芳环化合物及其应用
CN107115344B (zh) * 2017-03-23 2019-06-14 广东众生睿创生物科技有限公司 酪氨酸激酶抑制剂在制备用于预防和/或治疗纤维化疾病的药物中的用途
US10988466B2 (en) 2017-03-23 2021-04-27 Jacobio Pharmaceuticals Co., Ltd. Heterocyclic derivatives useful as SHP2 inhibitors
EP3384901B1 (en) 2017-04-04 2024-08-14 Synthon B.V. Pharmaceutical composition comprising lenvatinib mesylate
WO2018215668A1 (en) * 2017-05-26 2018-11-29 Glenmark Pharmaceuticals S.A. Novel inhibitors of map4k1
CN107513057A (zh) * 2017-09-06 2017-12-26 南京医科大学 一类乐伐替尼的乏氧活化前药及其应用
ES2932805T3 (es) * 2017-09-28 2023-01-26 Chongqing Pharmaceutical Industrial Res Institute Co Ltd Derivado de quinolina y aplicación del mismo como inhibidor de la tirosina quinasa
CN107739335A (zh) * 2017-12-01 2018-02-27 南京奇可药业有限公司 一种乐伐替尼的合成方法
EP3728248B1 (en) * 2017-12-18 2022-02-02 Chiesi Farmaceutici S.p.A. Azaindole derivatives as rho-kinase inhibitors
EP3730483B1 (en) * 2017-12-21 2023-08-30 Hefei Institutes of Physical Science, Chinese Academy of Sciences Class of pyrimidine derivative kinase inhibitors
JP7352569B2 (ja) 2018-01-10 2023-09-28 エーザイ・アール・アンド・ディー・マネジメント株式会社 肝細胞癌の治療のための併用療法
IL300824A (en) * 2018-01-26 2023-04-01 Exelixis Inc Compounds for the treatment of kinase-dependent disorders
US11673897B2 (en) 2018-01-26 2023-06-13 Exelixis, Inc. Compounds for the treatment of kinase-dependent disorders
US10583133B2 (en) 2018-03-12 2020-03-10 Shilpa Medicare Limited Pharmaceutical compositions of lenvatinib
CN108623521B (zh) * 2018-03-22 2020-09-04 盐城师范学院 一种乐伐替尼的制备方法
CA3091153A1 (en) 2018-03-28 2019-10-03 Eisai R&D Management Co., Ltd. Therapeutic agent for hepatocellular carcinoma
WO2019222075A1 (en) 2018-05-14 2019-11-21 Merck Sharp And Dohme Corp. Biomarkers for a combination therapy comprising lenvatinib and a pd-1 antagonist
CN110483482A (zh) * 2018-05-15 2019-11-22 北京诺诚健华医药科技有限公司 吲哚啉-1-甲酰胺类化合物、其制备方法及其在医药学上的应用
CN110590839B (zh) * 2018-06-13 2022-04-05 四川海思科制药有限公司 一种乐伐替尼衍生物及制备方法和用途
CN108690013A (zh) * 2018-07-02 2018-10-23 秦继伟 苯并[d]噻唑衍生物及其作为EGFR抑制剂在癌症治疗中的应用
CN108570044A (zh) * 2018-07-02 2018-09-25 秦继伟 一种酰胺类化合物及其合成方法和治疗癌症的用途
CN110845408A (zh) * 2018-08-20 2020-02-28 润佳（苏州）医药科技有限公司 同位素富集的乐伐替尼
EP3620452B1 (en) 2018-09-07 2021-05-19 Indena S.p.A. Process for the preparation of lenvatinib
EP3856726A1 (en) 2018-09-25 2021-08-04 Black Diamond Therapeutics, Inc. Quinazoline derivatives as tyrosine kinase inhibitor, compositions, methods of making them and their use
US20220062263A1 (en) * 2018-10-04 2022-03-03 Synthon B.V. Crystalline forms and processes of lenvatinib besylate
PT3632436T (pt) 2018-10-04 2022-07-22 Synthon Bv Composição farmacêutica compreendendo sais de lenvatinib
US20210349097A1 (en) 2018-10-05 2021-11-11 Eisai R&D Management Co., Ltd. Biomarkers for a combination therapy comprising lenvatinib and everolimus
EP3861346A1 (en) 2018-10-05 2021-08-11 Eisai R&D Management Co., Ltd. Biomarkers for a therapy comprising a sorafenib compound
CN111116468A (zh) * 2018-10-31 2020-05-08 正大天晴药业集团股份有限公司 用于治疗胰腺癌的喹啉类化合物或其药学上可接受的盐
CN113195000A (zh) 2018-12-21 2021-07-30 第一三共株式会社 抗体-药物缀合物和激酶抑制剂的组合
JP2020100598A (ja) 2018-12-25 2020-07-02 公益財団法人応用生化学研究所 レンバチニブ誘導体、並びにそれを用いた医薬研究用組成物及び腫瘍治療剤
CN115838369A (zh) 2019-03-19 2023-03-24 株式会社沃若诺伊 杂芳基衍生物、其制备方法、及含其作为有效成分的药物组合物
CN109776432B (zh) * 2019-03-21 2020-07-24 广州六顺生物科技股份有限公司 一种多靶点激酶抑制剂、药物组合物及多靶点激酶抑制剂的制备方法和应用
TW202104259A (zh) 2019-04-01 2021-02-01 日商凱依歐姆 生物科學股份有限公司 癌治療用醫藥
CA3135921C (en) * 2019-04-03 2024-04-16 Primegene (Beijing) Co., Ltd. Quinolyl-containing compound and pharmaceutical composition, and use thereof
CA3140017A1 (en) 2019-07-19 2021-01-28 Aurore HICK Polyaromatic urea derivatives and their use in the treatment of muscle diseases
US20220267444A1 (en) 2019-08-02 2022-08-25 CTTQ-Akeso (ShangHai) Biomed. Tech. Co., Ltd. Anti-pd-1 antibody and medical use thereof
CA3146780A1 (en) 2019-08-02 2021-02-11 Akeso Pharmaceuticals, Inc. Anti-ctla4/anti-pd-1 bispecific antibody and use thereof
CN110437223B (zh) * 2019-08-06 2022-11-25 江苏千之康生物医药科技有限公司 乐伐替尼酸的噻唑酮衍生物及其应用
WO2021217537A1 (zh) * 2020-04-30 2021-11-04 天津睿创康泰生物技术有限公司 一种乐伐替尼游离碱晶型及其制备方法
WO2021226547A2 (en) * 2020-05-08 2021-11-11 Halia Therapeutics, Inc. Targeted nek7 inhibition for modulation of the nlrp3 inflammasome
BR112022022669A2 (pt) 2020-05-08 2023-01-17 Halia Therapeutics Inc Inibidores de nek7 quinase
CN112194623A (zh) * 2020-10-16 2021-01-08 四川伊诺达博医药科技有限公司 一种乐伐替尼衍生物关键中间体的合成方法
CA3200386A1 (en) * 2020-12-29 2022-07-07 Seo Jung Han Novel naphthyridinone derivative having inhibitory activity against ectonucleotide pyrophosphatase-phosphodiesterase and use thereof
EP4029501A1 (en) 2021-01-19 2022-07-20 Anagenesis Biotechnologies Combination of polyaromatic urea derivatives and glucocorticoid or hdac inhibitor for the treatment of diseases or conditions associated with muscle cells and/or satellite cells
WO2022226182A1 (en) * 2021-04-22 2022-10-27 Halia Therapeutics, Inc. Nek7 inhibitors
CN113372270A (zh) * 2021-06-24 2021-09-10 江西国药有限责任公司 一种仑伐替尼及其制备方法
CN113582924A (zh) * 2021-09-09 2021-11-02 四川国康药业有限公司 一种多靶点酪氨酸激酶抑制剂及其制备方法和用途
EP4147689A1 (en) 2021-09-13 2023-03-15 Lotus Pharmaceutical Co., Ltd. Lenvatinib formulation
IL312506A (en) 2021-11-08 2024-07-01 Progentos Therapeutics Inc Platelet-based alpha inhibitors and their uses
CN115124534B (zh) * 2021-11-23 2023-09-15 中山大学 非核苷酸类prmt5小分子抑制剂、制备方法及用途
TW202345828A (zh) 2022-03-31 2023-12-01 日商衛材R&D企管股份有限公司 脂質體組合物及包含脂質體之醫藥組合物
WO2023225300A2 (en) * 2022-05-20 2023-11-23 Emory University Compounds and pharmaceutical compositions useful for managing sickle cell disease and conditions related thereto
WO2023228095A1 (en) 2022-05-24 2023-11-30 Daiichi Sankyo Company, Limited Dosage regimen of an anti-cdh6 antibody-drug conjugate
EP4289427A1 (en) * 2022-06-10 2023-12-13 Anagenesis Biotechnologies Dihydro[1,8]naphthyridin-7-one and pyrido[3,2-b][1,4]oxazin-3-one for use in treating cancer, and metastases in particular.

Family Cites Families (193)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US189629A (en) * 1877-04-17 Improvement in adjustable elastic buckets for chain-pumps
CU22545A1 (es) 1994-11-18 1999-03-31 Centro Inmunologia Molecular Obtención de un anticuerpo quimérico y humanizado contra el receptor del factor de crecimiento epidérmico para uso diagnóstico y terapéutico
US4526988A (en) 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
DE3587022T2 (de) 1984-02-17 1993-06-17 Genentech Inc Menschlicher transformationswachstumsfaktor und vorlaeufer oder fragment hiervon, zellen, dna, vektoren und verfahren zu ihrer herstellung, zusammensetzungen und produkte, die diese enthalten, sowie davon abgeleitete antikoerper und diagnostizierverfahren.
US4716102A (en) * 1984-08-15 1987-12-29 Regents Of The University Of California Purified AIDS-associated virus ARV-2
IL77133A (en) 1984-12-04 1991-01-31 Lilly Co Eli Antineoplastic pharmaceutical compositions containing pentofuranoside derivatives,some new such compounds and their preparation
JPS62168137A (ja) * 1985-12-20 1987-07-24 Fuji Photo Film Co Ltd ハロゲン化銀カラ−写真感光材料およびその処理方法
CA1339136C (en) 1987-07-01 1997-07-29 Sailesh Amilal Varia Amorphous form of aztreonam
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
US4983615A (en) 1989-06-28 1991-01-08 Hoechst-Roussel Pharmaceuticals Inc. Heteroarylamino- and heteroaryloxypyridinamine compounds which are useful in treating skin disorders
JPH0340486A (ja) 1989-07-07 1991-02-21 Asahi Chem Ind Co Ltd 印刷配線基板
JP2980326B2 (ja) 1989-08-31 1999-11-22 株式会社東芝 ディスク制御装置
US5180818A (en) 1990-03-21 1993-01-19 The University Of Colorado Foundation, Inc. Site specific cleavage of single-stranded dna
GB9105677D0 (en) 1991-03-19 1991-05-01 Ici Plc Heterocyclic compounds
US5367057A (en) 1991-04-02 1994-11-22 The Trustees Of Princeton University Tyrosine kinase receptor flk-2 and fragments thereof
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
US5721237A (en) 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
AU658646B2 (en) 1991-05-10 1995-04-27 Rhone-Poulenc Rorer International (Holdings) Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
JPH04341454A (ja) 1991-05-16 1992-11-27 Canon Inc シート収納装置
US5750376A (en) 1991-07-08 1998-05-12 Neurospheres Holdings Ltd. In vitro growth and proliferation of genetically modified multipotent neural stem cells and their progeny
EP0648264A4 (en) 1992-06-03 1997-10-01 Univ Case Western Reserve BANDAGE ALLOWING THE CONTINUOUS APPLICATION OF ORGANIC PRODUCTS.
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
GB9323290D0 (en) 1992-12-10 1994-01-05 Zeneca Ltd Quinazoline derivatives
JPH07176103A (ja) 1993-12-20 1995-07-14 Canon Inc 光磁気記録再生システムならびにこれに用いる磁気ヘッド及び光磁気記録媒体
GB9326136D0 (en) * 1993-12-22 1994-02-23 Erba Carlo Spa Biologically active 3-substituted oxindole derivatives useful as anti-angiogenic agents
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
US6811779B2 (en) 1994-02-10 2004-11-02 Imclone Systems Incorporated Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
JP3660391B2 (ja) 1994-05-27 2005-06-15 株式会社東芝 半導体装置の製造方法
JPH0848078A (ja) 1994-08-05 1996-02-20 Nippon Paper Ind Co Ltd 感熱記録体
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
US5656454A (en) 1994-10-04 1997-08-12 President And Fellows Of Harvard College Endothelial cell-specific enhancer
IL115256A0 (en) 1994-11-14 1995-12-31 Warner Lambert Co 6-Aryl pyrido (2,3-d) pyrimidines and naphthyridines and their use
GB9424249D0 (en) 1994-12-01 1995-01-18 T & N Technology Ltd Brake pads
JPH08176138A (ja) 1994-12-19 1996-07-09 Mercian Corp イソクマリン誘導体
US5658374A (en) 1995-02-28 1997-08-19 Buckman Laboratories International, Inc. Aqueous lecithin-based release aids and methods of using the same
US5624937A (en) * 1995-03-02 1997-04-29 Eli Lilly And Company Chemical compounds as inhibitors of amyloid beta protein production
US6579314B1 (en) 1995-03-10 2003-06-17 C.R. Bard, Inc. Covered stent with encapsulated ends
PT817775E (pt) 1995-03-30 2002-01-30 Pfizer Derivados de quinazolina
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
MX9709867A (es) 1995-06-07 1998-03-31 Pfizer Derivados de pirimidina condensados con un anillo heterociclico, composiciones que contienen los mismos, y uso de los mismos.
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
GB9514265D0 (en) 1995-07-13 1995-09-13 Wellcome Found Hetrocyclic compounds
JP3493903B2 (ja) * 1995-09-29 2004-02-03 株式会社デンソー 半導体装置
GB9520822D0 (en) 1995-10-11 1995-12-13 Wellcome Found Therapeutically active compounds
AR004010A1 (es) 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
US6346398B1 (en) 1995-10-26 2002-02-12 Ribozyme Pharmaceuticals, Inc. Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor
AU7340096A (en) * 1995-11-07 1997-05-29 Kirin Beer Kabushiki Kaisha Quinoline derivatives and quinazoline derivatives inhibiting autophosphorylation of growth factor receptor originating in platelet and pharmaceutical compositions containing the same
US5849759A (en) 1995-12-08 1998-12-15 Berlex Laboratories, Inc. Naphthyl-substituted benzimidazole derivatives as anti-coagulants
JPH09176103A (ja) 1995-12-28 1997-07-08 Nitto Chem Ind Co Ltd ハロメチルビフェニル誘導体の製造方法
GB9604361D0 (en) 1996-02-29 1996-05-01 Pharmacia Spa 4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors
NZ332173A (en) 1996-04-17 2000-06-23 Du Pont Pharm Co N-(amidinophenyl)-n'-(subst.)-3h-2,4-benzodiazepin-3-one derivatives as factor xa inhibitors
AU721130B2 (en) 1996-06-28 2000-06-22 Merck & Co., Inc. Fibrinogen receptor antagonists
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
EP0912572B1 (en) 1996-07-13 2003-01-15 Glaxo Group Limited Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
PT912559E (pt) 1996-07-13 2003-03-31 Glaxo Group Ltd Compostos heterociclicos fundidos como inibidores de proteina tirosina quinase
DE69733825T2 (de) 1996-09-25 2006-06-08 Astrazeneca Ab Chinolin-derivate die den effekt von wachstumsfaktoren wie vegf vezögern
CN1072657C (zh) 1996-09-30 2001-10-10 日本农药株式会社 1,2,3－噻二唑衍生物和其盐以及农业园艺病毒防治剂及其使用方法
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
US6413971B1 (en) 1996-11-27 2002-07-02 Pfizer Inc Fused bicyclic pyrimidine derivatives
WO1998032436A1 (en) 1997-01-29 1998-07-30 Eli Lilly And Company Treatment for premenstrual dysphoric disorder
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
AU732969B2 (en) * 1997-02-19 2001-05-03 Berlex Laboratories, Inc. (N)-heterocyclic derivatives as NOS inhibitors
US6090556A (en) 1997-04-07 2000-07-18 Japan Science & Technology Corporation Method for quantitatively determining the expression of a gene
WO1998050346A2 (en) 1997-04-18 1998-11-12 Smithkline Beecham Plc Acetamide and urea derivatives, process for their preparation and their use in the treatment of cns disorders
DE69826695T2 (de) 1997-05-23 2006-02-02 Bayer Pharmaceuticals Corp., West Haven Arylharnstoffderivate zur behandlung von inflammatorischen oder immunomodulatorischen erkrankungen
US6093742A (en) 1997-06-27 2000-07-25 Vertex Pharmaceuticals, Inc. Inhibitors of p38
AU8283898A (en) 1997-06-30 1999-01-25 University Of Maryland At Baltimore Heparin binding-epidermal growth factor in the diagnosis of interstitial cystitis
JP3765918B2 (ja) 1997-11-10 2006-04-12 パイオニア株式会社 発光ディスプレイ及びその駆動方法
JP4194678B2 (ja) * 1997-11-28 2008-12-10 キリンファーマ株式会社 キノリン誘導体およびそれを含む医薬組成物
DE1043995T1 (de) 1997-12-22 2001-06-07 Bayer Corp., Pittsburgh INHIBIERUNG DER p38 KINASE-AKTIVITÄT DURCH DIE VERWENDUNG VON ARYL- UND HETEROARYLSUBSTITUIERTEN HARNSTOFFEN
AU2198999A (en) 1997-12-22 1999-07-12 Bayer Corporation Inhibition of raf kinase using substituted heterocyclic ureas
WO1999032111A1 (en) 1997-12-22 1999-07-01 Bayer Corporation INHIBITION OF p38 KINASE ACTIVITY USING SUBSTITUTED HETEROCYCLIC UREAS
ES2153809T3 (es) 1997-12-22 2005-07-16 Bayer Pharmaceuticals Corporation Inhibicion de la cinasa raf por uso de difnil-ureas sustituidas simetrica y asimetricamente.
RS49779B (sr) 1998-01-12 2008-06-05 Glaxo Group Limited, Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
GB9800575D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
TR200002447T2 (tr) 1998-02-25 2000-11-21 Genetics Institute, Inc. Fosfolinaz enzimlerinin inhibitörleri
UA60365C2 (uk) 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
EE200100271A (et) 1998-11-19 2002-10-15 Warner-Lambert Company N-[4-(3-kloro-4-fluorofenüülamino)-7-(3-morfoliin-4-üülpropoksü)kinasoliin-6-üül]ak rüülamiid kui türosiinkinaaside pöördumatu inhibiitor
EP1140840B1 (en) 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
UA73492C2 (en) 1999-01-19 2005-08-15 Aromatic heterocyclic compounds as antiinflammatory agents
US6797823B1 (en) 1999-01-22 2004-09-28 Kirin Beer Kabushiki Kaisha Quinoline derivatives and quinazoline derivatives
JP3270834B2 (ja) 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク 抗がん剤として有用なヘテロ芳香族二環式誘導体
UA71945C2 (en) 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
PL205557B1 (pl) 1999-02-10 2010-05-31 Astrazeneca Ab Pochodne indolu
GB9904103D0 (en) 1999-02-24 1999-04-14 Zeneca Ltd Quinoline derivatives
JP2000328080A (ja) 1999-03-12 2000-11-28 Shin Etsu Chem Co Ltd シートベルト用低摩擦化処理剤
RS49836B (sr) 1999-03-31 2008-08-07 Pfizer Products Inc., Postupci i intermedijeri za dobijanje anti-kancernih jedinjenja
EP1185559A2 (en) 1999-04-28 2002-03-13 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting vegf
AU4778500A (en) 1999-05-20 2000-12-12 Takeda Chemical Industries Ltd. Composition containing ascorbic acid salt
JP4304357B2 (ja) 1999-05-24 2009-07-29 独立行政法人理化学研究所 完全長ｃＤＮＡライブラリーの作成法
PE20010306A1 (es) 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
AU6762400A (en) * 1999-08-12 2001-03-13 Cor Therapeutics, Inc. Inhibitors of factor xa
CO5200835A1 (es) 1999-09-28 2002-09-27 Bayer Corp Piridinas y piridacinas sustituidas con actividad de inhibicion de angiogenesis
UA75054C2 (uk) 1999-10-13 2006-03-15 Бьорінгер Інгельхайм Фарма Гмбх & Ко. Кг Заміщені в положенні 6 індолінони, їх одержання та їх застосування як лікарського засобу
JP2001131071A (ja) 1999-10-29 2001-05-15 Meiji Seika Kaisha Ltd 非晶質および非晶質を含有する医薬組成物
US20080241835A1 (en) 1999-11-01 2008-10-02 Genentech, Inc. Differentially expressed genes involved in angiogenesis, the polypeptides encoded thereby, and methods of using the same
AU784338B2 (en) 1999-11-01 2006-03-16 Curagen Corporation Differentially expressed genes involved in angiogenesis, the polypeptides encoded thereby, and methods of using the same
MXPA02004879A (es) * 1999-11-16 2002-08-30 Boehringer Ingelheim Pharma Derivados de urea como agentes antiinflamatorios.
UA75055C2 (uk) 1999-11-30 2006-03-15 Пфайзер Продактс Інк. Похідні бензоімідазолу, що використовуються як антипроліферативний засіб, фармацевтична композиція на їх основі
PT1255536E (pt) 1999-12-22 2006-09-29 Sugen Inc Derivados de indolinona para a modulacao da tirosina proteina cinase de tipo c-kit
EP1243582A4 (en) 1999-12-24 2003-06-04 Kirin Brewery CHINOLINE AND CHINAZOLINE DERIVATIVES AND MEDICATIONS CONTAINING THEM
AU2223501A (en) * 1999-12-24 2001-07-09 Kyowa Hakko Kogyo Co. Ltd. Fused purine derivatives
SK287142B6 (sk) 2000-02-15 2010-01-07 Sugen, Inc. Inhibítory proteínkináz na báze pyrolom substituovaného 2-indolinónu, farmaceutický prípravok s ich obsahom a ich použitie
WO2001096390A2 (en) 2000-06-09 2001-12-20 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer
WO2002016348A1 (en) 2000-08-09 2002-02-28 Astrazeneca Ab Antiangiogenic bicyclic derivatives
DE60134679D1 (de) 2000-10-20 2008-08-14 Eisai R&D Man Co Ltd Stickstoff enthaltende aromatische Heterozyklen
TWI283575B (en) 2000-10-31 2007-07-11 Eisai Co Ltd Medicinal compositions for concomitant use as anticancer agent
TW558430B (en) * 2000-11-01 2003-10-21 Kao Corp Cleaning device
DE60130017T2 (de) 2000-11-22 2008-05-15 Novartis Ag Kombination enthaltend ein mittel zur verminderung von vegf-aktivität und ein mittel zur verminderung von egf-aktivität
WO2002044156A2 (en) 2000-11-29 2002-06-06 Glaxo Group Limited Benzimidazole derivatives useful as tie-2 and/or vegfr-2 inhibitors
WO2002072578A2 (en) 2001-03-08 2002-09-19 Millennium Pharmaceuticals (homo) piperazine substituted quinolines for inhibiting the phosphorylation of kinases
PL363991A1 (en) 2001-04-06 2004-11-29 Wyeth Antineoplastic combinations such as rapamycin together with gemcitabine or fluorouracil
US6821987B2 (en) * 2001-04-27 2004-11-23 Kirin Beer Kabushiki Kaisha Quinoline derivatives and quinazoline derivatives having azolyl group
CZ299756B6 (cs) 2001-05-16 2008-11-12 Novartis Ag Kombinace s obsahem N-{5-[4-(4-methyl-piperazino-methyl)benzoylamido]-2-methylfenyl}-4-(3-pyridyl)-2-pyrimidin-aminu k lécení proliferativních onemocnení
DE60233736D1 (de) 2001-06-22 2009-10-29 Kirin Pharma K K Chinolinderivat und chinazolinderivat, die die selbstphosphorylierung des hepatocytus-proliferator-rezeptors hemmen, und diese enthaltende medizinische zusammensetzung
GB0117144D0 (en) 2001-07-13 2001-09-05 Glaxo Group Ltd Process
GB0119467D0 (en) 2001-08-09 2001-10-03 Smithkline Beecham Plc Novel compound
EP1436620B1 (en) 2001-09-10 2014-04-23 Meso Scale Technologies, LLC Methods and apparatus for conducting multiple measurements on a sample
EP1427379B1 (en) 2001-09-20 2008-08-13 AB Science Use of potent, selective and non toxic c-kit inhibitors for treating interstitial cystitis
US20040266779A1 (en) 2001-09-27 2004-12-30 Anderson Kenneth C. Use of c-kit inhibitors for the treatment of myeloma
CA2461812C (en) 2001-09-27 2011-09-20 Allergan, Inc. 3-(arylamino)methylene-1,3-dihydro-2h-indol-2-ones as kinase inhibitors
AU2002340139A1 (en) 2001-10-09 2003-04-22 The University Of Cincinnati Inhibitors of the egf receptor for the treatment of thyroid cancer
WO2003033472A1 (fr) 2001-10-17 2003-04-24 Kirin Beer Kabushiki Kaisha Derives de quinoline ou de quinazoline inhibant l'autophosphorylation de recepteurs du facteur de croissance des fibroblastes
MXPA04004969A (es) 2001-11-27 2004-08-11 Wyeth Corp 3-cianoquinolinas como inhibidores del receptor del factor de crecimiento epidermico y her2 cinasas.
GB0201508D0 (en) 2002-01-23 2002-03-13 Novartis Ag Organic compounds
EP1481678A4 (en) 2002-03-05 2009-12-30 Eisai R&D Man Co Ltd ANTITUMORAL AGENT CONTAINING A SULFONAMIDE-CONTAINING HETEROCYCLIC COMPOUND AND AN ANGIOGENESIS INHIBITOR
WO2003079020A2 (en) 2002-03-20 2003-09-25 Dana-Farber Cancer Institute Inc. Methods and compositions for the identification, assessment, and therapy of small cell lung cancer
WO2003093238A1 (fr) 2002-05-01 2003-11-13 Kirin Beer Kabushiki Kaisha Derives de quinoleine et derives de quinazoline inhibiteurs de l'autophosphorylation du recepteur du facteur stimulant la proliferation des macrophages
UA77303C2 (en) 2002-06-14 2006-11-15 Pfizer Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
WO2004006862A2 (en) 2002-07-16 2004-01-22 Children's Medical Center Corporation A method for the modulation of angiogenesis
US7169936B2 (en) 2002-07-23 2007-01-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinone derivatives substituted in the 6-position, their preparation and their use as medicaments
CN100339376C (zh) 2002-08-30 2007-09-26 卫材R&D管理有限公司 含氮芳环衍生物
KR20050051688A (ko) 2002-10-09 2005-06-01 코산 바이오사이언시즈, 인코포레이티드 에포틸론(Еｐｏ) Ｄ ＋ 5-플루오로우라실(ＦＵ)/겜시타빈
GB0223380D0 (en) 2002-10-09 2002-11-13 Astrazeneca Ab Combination therapy
US8697094B2 (en) 2002-10-16 2014-04-15 Takeda Pharmaceutical Company Limited Stable solid preparations
JP4749660B2 (ja) 2002-10-16 2011-08-17 武田薬品工業株式会社 安定な固形製剤
WO2004039782A1 (ja) 2002-10-29 2004-05-13 Kirin Beer Kabushiki Kaisha Ｆｌｔ３自己リン酸化を阻害するキノリン誘導体およびキナゾリン誘導体並びにそれらを含有する医薬組成物
AU2003276453A1 (en) 2002-11-06 2004-06-07 Cyclacel Limited Pharmaceutical composition comprising a cdk inhibitor and gemcitabine
GB0226434D0 (en) 2002-11-13 2002-12-18 Astrazeneca Ab Combination product
ITSV20020056A1 (it) 2002-11-14 2004-05-15 Alstom Transp Spa Dispositivo e metodo di verifica di motori software logici di comando di impianti ferroviari, in particolare di impianti di stazione
AR042042A1 (es) 2002-11-15 2005-06-08 Sugen Inc Administracion combinada de una indolinona con un agente quimioterapeutico para trastornos de proliferacion celular
US7399866B2 (en) 2003-01-14 2008-07-15 Cytokinetics, Inc. Compounds, compositions, and methods
NL1022425C2 (nl) 2003-01-17 2004-08-03 Trespa Int Bv Fenolhars, toepassing van een dergelijk fenolhars alsmede een daarmee vervaardigd vormdeel.
JP3581361B1 (ja) 2003-02-17 2004-10-27 株式会社脳機能研究所 脳活動測定装置
MY143789A (en) 2003-02-18 2011-07-15 Helsinn Healthcare Sa Use of palonosetron treating post- operative nausea and vomiting
KR20050117533A (ko) 2003-03-05 2005-12-14 셀진 코포레이션 디페닐에틸렌 화합물 및 그의 용도
EP1604665B1 (en) 2003-03-10 2011-05-11 Eisai R&D Management Co., Ltd. C-kit kinase inhibitor
CN101928284A (zh) 2003-03-14 2010-12-29 小野药品工业株式会社 含氮杂环衍生物以及包含所述化合物作为活性成分的药物
CN1761682A (zh) 2003-03-14 2006-04-19 大正制药株式会社 单克隆抗体与产生该单克隆抗体的杂交瘤
DE10317649A1 (de) 2003-04-17 2004-11-04 Robert Bosch Gmbh Verfahren und Vorrichtung zum Betreiben eines Verbrennungsmotors im Schiebebetrieb
US20070117842A1 (en) 2003-04-22 2007-05-24 Itaru Arimoto Polymorph of 4-[3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy]-7-methoxy-6- quinolinecarboxamide and a process for the preparation of the same
JP2005008534A (ja) 2003-06-17 2005-01-13 Soc De Conseils De Recherches & D'applications Scientifiques (Scras) 抗癌剤及び癌の治療方法
KR20120093411A (ko) 2003-07-10 2012-08-22 아스트라제네카 아베 백금 화합물 및 임의적으로 이온화 방사능과 조합된 퀴나졸린 유도체 ｚｄ6474의 혈관신생 및/또는 증가된 혈관 투과성 관련 질환 치료 용도
EP1653934B1 (en) 2003-08-15 2008-05-14 AB Science Use of c-kit inhibitors for treating type ii diabetes
CN1852905A (zh) 2003-08-21 2006-10-25 Osi制药公司 具有n－取代的苯并咪唑基的c－kit抑制剂
JP2007505938A (ja) 2003-09-23 2007-03-15 ノバルティス アクチエンゲゼルシャフト Ｖｅｇｆ受容体阻害剤と化学療法剤の組み合わせ
EP2609919A3 (en) 2003-09-26 2014-02-26 Exelixis, Inc. c-Met modulators and methods of use
JP2005124034A (ja) 2003-10-20 2005-05-12 Nippon Telegr & Teleph Corp <Ntt> 発信者の特定及び発信者への呼び返しを可能とする回線設定方法
EP1683785B1 (en) 2003-11-11 2013-10-16 Eisai R&D Management Co., Ltd. Urea derivative and process for producing the same
PE20051046A1 (es) 2003-11-28 2006-01-11 Novartis Ag Derivados de diaril-urea en el tratamiento de enfermedades dependientes de la quinasa de proteina
SG149004A1 (en) 2003-12-05 2009-01-29 Bristol Myers Squibb Co Inhibitors of type 2 vascular endothelial growth factor receptors
AU2004309217B2 (en) 2003-12-25 2008-11-06 Eisai R&D Management Co., Ltd Crystal of salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)amino-phenoxy)-7-methoxy-6-quinolinecarboxamide or of solvate thereof and processes for producing these
JPWO2005082855A1 (ja) 2004-02-27 2007-10-25 エーザイ・アール・アンド・ディー・マネジメント株式会社 新規ピリジン誘導体およびピリミジン誘導体（２）
KR20050091462A (ko) 2004-03-12 2005-09-15 한국과학기술연구원 푸로피리미딘 화합물 및 이를 포함하는 ｄｄｒ2 티로신키나아제 활성 저해제
CA2567836A1 (en) 2004-06-03 2005-12-15 F. Hoffmann-La Roche Ag Treatment with gemcitabine and an egfr-inhibitor
US8772269B2 (en) 2004-09-13 2014-07-08 Eisai R&D Management Co., Ltd. Use of sulfonamide-including compounds in combination with angiogenesis inhibitors
WO2006030941A1 (ja) 2004-09-13 2006-03-23 Eisai R & D Management Co., Ltd. スルホンアミド含有化合物の血管新生阻害物質との併用
ES2322175T3 (es) 2004-09-17 2009-06-17 EISAI R&amp;D MANAGEMENT CO., LTD. Composicion medicinal con estabilidad mejorada y gelificacion reducida.
US20060079494A1 (en) 2004-09-27 2006-04-13 Santi Daniel V Specific kinase inhibitors
JP2008520746A (ja) 2004-11-22 2008-06-19 キング・ファーマシューティカルズ・リサーチ・アンド・デベロプメント・インコーポレイティッド アデノシンａ３受容体アンタゴニストを用いる癌及びｈｉｆ−１が介在する疾患の促進的治療
JP2008523072A (ja) 2004-12-07 2008-07-03 ルーカス ファーマシューティカルズ， インコーポレイテッド タンパク質キナーゼの阻害剤
AU2006217692A1 (en) 2005-02-28 2006-08-31 Eisai R & D Management Co., Ltd. Novel combinational use of sulfonamide compound
JP5106098B2 (ja) 2005-02-28 2012-12-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 スルホンアミド化合物の抗癌剤との新規併用
DE102005017446B4 (de) * 2005-04-15 2008-06-05 Südzucker AG Mannheim/Ochsenfurt Temperaturführung bei der alkalischen Extraktion
US7550483B2 (en) 2005-06-23 2009-06-23 Eisai R&D Management Co., Ltd. Amorphous salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide and process for preparing the same
CN101233111A (zh) 2005-06-23 2008-07-30 卫材R&D管理有限公司 4-（3-氯-4-（环丙基氨基羰基）氨基苯氧基）-7-甲氧基-6-喹啉羧酸酰胺的无定形盐及其制备方法
WO2007014335A2 (en) 2005-07-27 2007-02-01 The University Of Texas System Combinations comprising gemcitabine and tyrosine kinase inhibitors for the treatment of pancreatic cancer
WO2007015569A1 (ja) 2005-08-01 2007-02-08 Eisai R & D Management Co., Ltd. 血管新生阻害物質の効果を予測する方法
JP4989476B2 (ja) 2005-08-02 2012-08-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 血管新生阻害物質の効果を検定する方法
US20090053236A1 (en) 2005-11-07 2009-02-26 Eisai R & D Management Co., Ltd. USE OF COMBINATION OF ANTI-ANGIOGENIC SUBSTANCE AND c-kit KINASE INHIBITOR
EP1964837A4 (en) 2005-11-22 2010-12-22 Eisai R&D Man Co Ltd Antitumor agent against multiple myeloma
AR059066A1 (es) 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
WO2007136103A1 (ja) 2006-05-18 2007-11-29 Eisai R & D Management Co., Ltd. 甲状腺癌に対する抗腫瘍剤
US8238322B2 (en) * 2006-06-30 2012-08-07 Nokia Corporation Optimizing of channel allocation in a wireless communications system
WO2008026748A1 (fr) 2006-08-28 2008-03-06 Eisai R & D Management Co., Ltd. Agent antitumoral pour cancer gastrique non différencié
US20080057195A1 (en) * 2006-08-31 2008-03-06 United Technologies Corporation Non-line of sight coating technique
CA2675736A1 (en) 2007-01-19 2008-07-24 Eisai R&D Management Co., Ltd. Composition for treatment of pancreatic cancer
KR101445892B1 (ko) 2007-01-29 2014-09-29 에자이 알앤드디 매니지먼트 가부시키가이샤 미분화형 위암 치료용 조성물
JPWO2008111441A1 (ja) 2007-03-05 2010-06-24 協和発酵キリン株式会社 医薬組成物
WO2008108386A1 (ja) 2007-03-05 2008-09-12 Kyowa Hakko Kirin Co., Ltd. 医薬組成物
US8952035B2 (en) 2007-11-09 2015-02-10 Eisai R&D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
WO2009111648A1 (en) 2008-03-05 2009-09-11 Vicus Therapeutics, Llc Compositions and methods for mucositis and oncology therapies
CA2723617A1 (en) 2008-05-14 2009-11-19 Amgen Inc. Combinations vegf(r) inhibitors and hepatocyte growth factor (c-met) inhibitors for the treatment of cancer

Also Published As

Publication number Publication date
JP3712393B2 (ja) 2005-11-02
AU9598601A (en) 2002-04-29
US7612092B2 (en) 2009-11-03
NO2015021I1 (no) 2015-10-19
NO326781B1 (no) 2009-02-16
CA2426461C (en) 2011-04-12
DE60137273D1 (de) 2009-02-12
TWI304061B (en) 2008-12-11
CN1478078A (zh) 2004-02-25
EP1506962A2 (en) 2005-02-16
ES2318649T3 (es) 2009-05-01
US8372981B2 (en) 2013-02-12
ATE355275T1 (de) 2006-03-15
NO20031731D0 (no) 2003-04-14
EP1415987A1 (en) 2004-05-06
NO2015021I2 (no) 2015-10-08
LU92858I2 (fr) 2015-12-23
IL189677A0 (en) 2008-06-05
US20060160832A1 (en) 2006-07-20
EP1777218A1 (en) 2007-04-25
KR20030040552A (ko) 2003-05-22
KR100589032B1 (ko) 2006-06-14
AU2001295986B2 (en) 2006-08-17
EP1777218B1 (en) 2008-12-31
HUP0302603A3 (en) 2010-03-29
KR20050108426A (ko) 2005-11-16
FR15C0070I1 (es) 2015-04-12
US7973160B2 (en) 2011-07-05
RU2264389C3 (ru) 2018-06-01
US7253286B2 (en) 2007-08-07
US20060247259A1 (en) 2006-11-02
CN101029022B (zh) 2011-01-12
JP4354929B2 (ja) 2009-10-28
DE60126997D1 (de) 2007-04-12
RU2264389C2 (ru) 2005-11-20
HUP0302603A2 (hu) 2003-11-28
FR15C0070I2 (fr) 2016-02-12
CN1308310C (zh) 2007-04-04
NO20074657L (no) 2003-06-19
EP1415987B1 (en) 2007-02-28
KR100600550B1 (ko) 2006-07-13
JP2009215313A (ja) 2009-09-24
US20110118470A1 (en) 2011-05-19
NL300764I1 (es) 2015-12-29
PT1415987E (pt) 2007-05-31
NZ525324A (en) 2005-03-24
BE2015C055I2 (es) 2021-01-28
US20100197911A1 (en) 2010-08-05
AU2006236039B2 (en) 2008-05-22
HUS1600009I1 (hu) 2018-05-02
NO20031731L (no) 2003-06-19
US20040053908A1 (en) 2004-03-18
IL155447A (en) 2008-06-05
MXPA03003362A (es) 2003-08-01
EP1506962B1 (en) 2008-07-02
EP1415987A4 (en) 2004-08-18
JPWO2002032872A1 (ja) 2004-02-26
CN101029022A (zh) 2007-09-05
ATE419239T1 (de) 2009-01-15
HU230302B1 (hu) 2015-12-28
CN101024627A (zh) 2007-08-29
DK1415987T3 (da) 2007-07-02
ES2282299T3 (es) 2007-10-16
DE60126997T2 (de) 2007-10-25
DE60134679D1 (de) 2008-08-14
CA2426461A1 (en) 2002-04-25
AU2001295986A1 (en) 2002-07-04
ATE399766T1 (de) 2008-07-15
AU2006203099A1 (en) 2006-08-10
WO2002032872A1 (en) 2002-04-25
JP5086304B2 (ja) 2012-11-28
WO2002032872A8 (en) 2002-09-26
CY2015037I1 (el) 2016-04-13
IL155447A0 (en) 2003-11-23
NL300764I2 (es) 2015-12-29
AU2006236039A1 (en) 2006-12-07
JP2005272474A (ja) 2005-10-06
CY1107491T1 (el) 2013-03-13
EP1506962A3 (en) 2005-03-02
CY2015037I2 (el) 2016-04-13

Similar Documents

Publication Publication Date Title
AU9598601A (en) Nitrogenous aromatic ring compounds
SG77195A1 (en) Fungicidal 2-methoxybenzophenones
IL165502A0 (en) Method for preparing 3-halo-4,5-dihydro-1h-pyrazoles
SI1385514T1 (sl) Spiroindenske in spiroindanske spojine
HK1102812A1 (en) Crystalline forms of (r)-8-chloro-1-methyl- 2,3,4,5-tetrahydro-1h-3- benzazepine hydrochloride
HK1076816A1 (es)
EP0798288A4 (en) TRICYCLIC COMPOUNDS
CA2433874A1 (en) Improved process for carbapenem synthesis
AU4249700A (en) Hydroxamic acid derivative
HU9800865D0 (en) Condensed piperidine compounds
CA2402390A1 (en) Process for the preparation of pyrimidone derivatives with antifungal activity
HU9501466D0 (en) Glycopyranoside benzothiophenes
HK1054745A1 (en) Processes for the preparation of carbapenem-type antibacterial agents
EP1028118A4 (en) METHOD FOR PRODUCING 3-CEPHEM COMPOUNDS
IL162788A (en) Process for preparing a tripeptide and salt thereof
EP1229029A4 (en) METHOD FOR PRODUCING A BENZYLAMINE CONNECTION
EP1475382A4 (en) COMPOUNDS AS INHIBITORS OF SEMAPHORIN
EP1557407A4 (en) NEW ALPHA-CETOAMIDE DERIVATIVE AND USE THEREOF
TW288012B (es)

Legal Events

Date Code Title Description
FG Grant or registration
GB Transfer or rights